{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-034743","form_type":"8-K","ticker":"MED","cik":"0000910329","company_name":"MEDIFAST INC","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.269978+00:00","generated_at":"2026-05-31T13:20:24.608192+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Medifast Q2 revenue falls 43% to $168.6M; net loss $0.75/share, guides Q3 loss","bullets":["Revenue $168.6M, down 43.1% YoY; active earning Coaches 33,900 (-36.2%); avg revenue per Coach $4,972 (-10.9%).","GAAP net loss $8.2M ($0.75 loss per diluted share); non-GAAP adjusted net income $10.1M ($0.92 EPS).","Q3 2024 revenue guidance $125M-$145M; diluted loss per share expected $0.05-$0.70.","Cash, equivalents and securities $163.5M; no debt; CEO cites transformation and LifeMD collaboration.","Gross margin improved to 73.2% (non-GAAP 74.8%); SG&A rose to 77.9% of revenue due to fixed-cost deleverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-034743","json":"https://secwatch.observer/filing/0001628280-24-034743.json","markdown":"https://secwatch.observer/filing/0001628280-24-034743.md","text":"https://secwatch.observer/filing/0001628280-24-034743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/910329/000162828024034743/0001628280-24-034743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910329/000162828024034743/med-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:20:24.608192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}